|
KMID : 0360220100510081071
|
|
Journal of the Korean Ophthalmological Society
2010 Volume.51 No. 8 p.1071 ~ p.1076
|
|
|
Intravitreal Triamcinolone Versus Bevacizumab for Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion
|
|
Kim Ho-Soong
Moon Sang-Jeong
Kang Jae-Hoon
Yoon Hee-Sung
|
|
|
Abstract
|
|
|
Purpose: To compare clinical outcomes after intravitreal injection of triamcinolone acetonide or bevacizumab for the treatment of macular edema secondary to branch retinal vein occlusion.
Methods: Sixty-six patients received an intravitreal injection of either triamcinolone acetonide or bevacizumab. Patients were retrospectively reviewed. Thirty-three out of 66 patients were treated with an intravitreal injection of triamcinolone acetonide, while the other 33 patients received a bevacizumab injection. All patients underwent a visual acuity test, optical coherence tomography imaging and ophthalmoscopic examination throughout the follow-up.
Results: In the triamcinolone group, central macular thickness (CMT) decreased from 496.69 ± 153.01 μm at baseline to 313.06 ± 150.14 μm at the six-month follow-up visit, while in the bevacizumab group, CMT decreased from 441.30 ± 185.79 μm to 295.67 ± 188.80 μm (p＜0.05). In the triamcinolone group, best-corrected visual acuity (BCVA) improved from logMAR 0.92 ± 0.70 at baseline to logMAR 0.53 ± 0.43 at the six-month follow-up visit, and in the bevacizumab group, BCVA improved from logMAR 0.74 ± 0.47 to logMAR 0.34 ± 0.33 (p＜0.05).
Conclusions: The therapeutic effects of intravitreal triamcinolone acetonide showed no significant differences compared with those of intravitreal bevacizumab with regard to anatomical and functional outcomes. J Korean Ophthalmol Soc 2010;51(8):1071-1076
|
|
|
KEYWORD
|
|
|
Bevacizumab, Branch retinal vein occlusion, Macular edema, Triamcinolone
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|